Broadcast Date: 
  • Time: 

The meteoric rise in biotherapeutic antibody production is directly linked to their clinical success in treating a wide range of diseases and providing transformative medicines to patients. Evaluation of potentially therapeutic antibodies has historically been a slow and tedious task consuming large amounts of researchers’ valuable time. However, in recent years, high-throughput surface plasmon resonance select SPR) has streamlined the way investigators approach their drug discovery workflows. The ability to characterize binding kinetics, affinity, and epitope specificity on large antibody panels with minimal sample consumption at early stage research is accelerating the library-to-lead triage. In this GEN webinar, you will learn how high throughput SPR can be used to rapidly generate high-quality kinetic data from 384 antibodies in parallel from crude material and with minimal sample requirements. Additionally, we will demonstrate how epitope binning assays can be performed routinely on up to 384 antibodies per array, facilitating the identification of clones targeting unique epitopes.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Produced with support from:

Kathryn H. Ching, PhD
Senior Scientist
Ligand Pharmaceuticals

Yasmina Noubia Abdiche, PhD
Chief Scientific Officer